We discovered immune-modulated signaling pathways enriched for somatic mutations implicated in TNBC, among them, the natural killer cell, phagosome formation, interleukin 4, p53, death receptor and apoptosis, the role of BRCA1 in DNA damage response, molecular mechanisms of cancer, hereditary breast cancer, ERBB, PI3K/AKT, MYC, and HER-2 signaling pathways implicated in TNBC [6,7], suggesting that such pathways could serve as therapeutic targets. This evidence concerns the gene MYC and cancer.